Fig. 4
From: Development of a peptide targeting dopamine transporter to improve ADHD-like deficits
TAT-DATNT alleviated the hyperactivity of spontaneously hypertension rats. a-d, The effects of TAT-DATNT peptide treatment on locomotor behavior in WKY and SHR rats (n = 6–8 per group). a SHR rats manifested a significantly higher level of baseline locomotor activity compared to the control strain WKY rats (p < 0.001). b TAT-DATNT, at 0.4 nmol, alleviated the hyperactivity of SHR rats as compared to the TAT control (p < 0.01). c TAT-DATNT at 4 nmol exacerbated the hyperactivity of SHR rats compared to the TAT-treated SHR rats (p < 0.01). d TAT-DATNT displayed an U-shaped dose-response curve in SHR rats. e-h The effects of TAT-DATNT (at 0.4 nmol) on the D2R-DAT interaction in SHR rats (n = 3 for TAT, and 4 for TAT-DATNT). e TAT-DATNT reduced the level of D2R-DAT complex in SHR rats, as compared to those from TAT-injected group. f-h Densitometric analysis of DAT co-immunoprecipitation (CoIP) and D2R immunoprecipitation (D2R IP) from striatal lysate of SHR rats injected with TAT, or TAT-DATNT peptide. Results for each sample are presented as the ratio of the TAT samples. Data were analyzed by t-test. *p < 0.05, **p < 0.01, ***p < 0.001. Data are shown as mean ± S.E.M